Aptose Biosciences (APTO) announced that the Cohort Safety Review Committee – CSRC – monitoring Aptose’s Phase 1/2 TUSCANY trial of tuspetinib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback